On The Web
FEEDNovaBay Launches Clinical Study For Non-Antibiotic Treatment Of Impetigo, One Of The Most Common Skin Infections
- 11:32 AM — Sep 11 —
- Source: PharmaInfo.net
(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo. Read More
NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
- 6:40 AM — Sep 10 —
- Source: StockWatch
(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), ( http://www.novabaypharma.com ), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo. Read More
Impetigo
Biography
Bloomington, IL's Impetigo is a generally unheralded pioneer of the early death/gore/grind metal movement, distinguished by ... Read the full Impetigo bio.
Impetigo
Videos
We are currently searching for Impetigo videos...
Impetigo
